latest
Market/Novel Tech Articles

EMA exit from London may be sooner than originally anticipated creating additional uncertainty for drug approvals

A UK newspaper, The Guardian, has reported that EU officials will shortly be scheduling the transfer of EU agencies out of the UK as part of the Brexit divorce proceedings. In a report on April 15th, the paper identified two agencies in particular, the European Banking Authority (EBA) and the European Medicines Agency (EMA), indicating […]

Read full story

UK gene therapy company, NightstaRx Ltd., launches Phase I / II gene therapy study for treatment of X-linked retinitis pigmentosa

A UK clinical stage biotech company, NightstaRx, has announced the enrolment of the first patient in a Phase I / II gene therapy study for the treatment of X-linked retinitis pigmentosa (RP). RP is one of the most common retinal dystrophies affecting approximately 1 in 4,000 of the population, while the X-linked form is estimated […]

Read full story

Allergan (NYSE:AGN) and CRISPR company, Editas Medicine Inc. (NASDAQ:EDIT), announce strategic deal to focus on eye diseases

Allergan Inc. (NASDAQ:AGN) and Editas Medicine Inc. (NASDAQ:EDIT) have announced the execution of an exclusive licensing transaction in which Allergan receives an option on up to five of Editas’ CRISPR ocular research programmes, including Editas’ lead programme for a product candidate to treat Lebers congenital amaurosis (LCA10). Under the terms of the deal Editas will […]

Read full story

Related Market/Novel Tech News